These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3137682)

  • 21. Modulation of prostacyclin/thromboxane formation by molsidomine during platelet-endothelial cell interactions.
    Bordet JC; Lagarde M
    Biochem Pharmacol; 1988 Oct; 37(20):3911-4. PubMed ID: 3142481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats.
    Feuerstein G; Bayorh MA; Stull R; Goldstein DS; Zerbe RL; Ramwell PW; Faden AI
    Circ Shock; 1985; 17(3):223-32. PubMed ID: 3841032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between dose, pharmacokinetics, plasma-concentrations and antithrombotic effects of nafazatrom.
    Philipp E; Ritter W; Patzschke K
    Thromb Res Suppl; 1983; 4():129-33. PubMed ID: 6579706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antithrombotic effects of molsidomine alone and in combination with other antithrombotic agents in a thrombosis model of the microcirculation of the rat].
    Giedrojc J; Weichert W; Breddin HK
    Z Kardiol; 1991; 80 Suppl 5():35-9. PubMed ID: 1663678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reaction of the antithrombotic and antimetastatic agent, nafazatrom, with oxidizing radicals.
    Sevilla MD; Neta P; Marnett LJ
    Biochem Biophys Res Commun; 1983 Sep; 115(3):800-6. PubMed ID: 6312995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog.
    Fiedler VB; Mardin M
    J Cardiovasc Pharmacol; 1985; 7(5):983-9. PubMed ID: 2413312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral nafazatrom in man: effect on inhaled antigen challenge.
    Fuller RW; Maltby N; Richmond R; Dollery CT; Taylor GW; Ritter W; Philipp E
    Br J Clin Pharmacol; 1987 Jun; 23(6):677-81. PubMed ID: 3038156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individual and combined effects of a thromboxane receptor antagonist and different antithrombotic agents in a rat microcirculatory thrombosis model.
    Giedrojc J; Fellier H; Breddin HK
    Haemostasis; 1992; 22(6):322-9. PubMed ID: 1335951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonging prostacyclin production by nafazatrom or dipyridamole.
    Deckmyn H; Gresele P; Arnout J; Todisco A; Vermylen J
    Lancet; 1984 Aug; 2(8399):410-1. PubMed ID: 6147492
    [No Abstract]   [Full Text] [Related]  

  • 31. Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bay g 6575.
    Carreras LO; Chamone DA; Klerckx P; Vermylen J
    Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):663-70. PubMed ID: 7003804
    [No Abstract]   [Full Text] [Related]  

  • 32. Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat.
    Fiedler VB
    Eur J Pharmacol; 1983 Mar; 88(2-3):263-7. PubMed ID: 6852112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antithrombotic effects of molsidomine, isosorbide dinitrate and verapamil in a laser-induced thrombosis model].
    Krupiński K; Breddin H; Bielawiec M
    Kardiol Pol; 1993 Aug; 39(8):100-4. PubMed ID: 8231003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of prostaglandin modulators on prostate tumor growth and metastasis.
    Drago JR; Al-Mondhiry HA
    Anticancer Res; 1984; 4(6):391-4. PubMed ID: 6393859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological modulation of responses of guinea-pig airways contracted with arachidonic acid.
    Burka JF
    Br J Pharmacol; 1985 Jun; 85(2):421-5. PubMed ID: 2992662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effect of SIN-1 on thromboxane and prostacyclin formation in platelets and endothelial cells.
    Lagarde M; Bordet JC; Croset M
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S95-7. PubMed ID: 2484709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease.
    Roy L; Mehta J; Mehta P
    Am Heart J; 1985 May; 109(5 Pt 1):1026-31. PubMed ID: 3158183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effects of nafazatrom on ischemic reperfused myocardium.
    Shea MJ; Murtagh JJ; Jolly SR; Abrams GD; Pitt B; Lucchesi BR
    Eur J Pharmacol; 1984 Jun; 102(1):63-70. PubMed ID: 6479219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of Viagra with the NO donors molsidomine and RE 2047 with regard to antithrombotic and blood pressure lowering activities.
    Rehse K; Scheffler H; Reitner N
    Arch Pharm (Weinheim); 1999 May; 332(5):182-4. PubMed ID: 10366905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis.
    Shea MJ; Driscoll EM; Romson JL; Pitt B; Lucchesi BR
    Am Heart J; 1984 Apr; 107(4):629-37. PubMed ID: 6702555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.